Characterizing the open access and Creative Commons licence landscape for pharma-funded and non-commercial research

Read full text Summarise with VIRAT
Authors: Joanna L Donnelly, Jo Gordon, Alison Chisholm
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Presented at the 2026 European Meeting of the International Society for Medical Publication Professionals (ISMPP), 26–28 January 2026, London, UK.Objective Publishing open access (OA) under the Creative Commons (CC) Attribution (BY) licence ensures immediate availability of content and unrestricted reuse provided attribution is given. Journals’ licensing policies can impact optimal dissemination of pharma-funded research. We characterised disclosed OA/CC BY policies across biomedical journals and assessed how easy it was to find this information. Research Design and Methods We used the Open Pharma dashboard to identify peer-reviewed journals that published the most biomedical research articles (pharma-sponsored and non-commercial) in the preceding 12–24 months (to 11 March 2025).1 Each journal’s website was reviewed for up to 30 minutes to identify information on OA status, CC BY availability and any restrictions on CC BY use. Ease of information retrieval was based on time required to locate all pre-specified fields (‘easy’, 30 minutes). ResultsOf 55 journals, most (63%, 35/55) were fully OA, 33% (18/55) were mixed OA/pay-per-view (hybrid), and 4% (2/55) were subscription-only. All OA and hybrid journals offered a CC BY option, but 37% (20/33) refused CC BY use for some funders, including pharma. Journal-specified reasons for refusing CC BY use included the commercial nature of affected funders (n=9) and funders’ lack of OA mandate (n=7). OA and CC BY information was ‘easy’ (44%, 24/55) or ‘somewhat easy’ (47%, 26/55) to find for almost all journals. ConclusionsOA and CC BY policies were generally easy to find, but over one-third of journals refused CC BY use for pharma-sponsored research. CC BY restrictions impede optimal research dissemination and undermine research trust; pharma-funder OA mandates may help address some barriers to CC BY use. References 1. Open Pharma Open Access Dashboard (2024) Available at: https://www.lens.org/lens/report/view/Open-access-dashboard/14572/page/14573 (Accessed 13 October 2025)

Fields of Study & Subjects

Academic Publishing and Open Access Publishing and Scholarly Communication scientometrics and bibliometrics research

Publication details

Journal / source
Figshare
Publication date
25 March 2026
Language
EN